This approval converts RVMD from a pure-play clinical-stage biotech to a commercial-stage company with a priced product. Monitor initial prescription volumes, payer coverage decisions, and any competitor RAS inhibitor developments. The high market cap already reflects substantial optimism, but the data and pricing support a multi-billion peak sales opportunity if RASONQUE delivers meaningful survival benefit.
Price Chart
Executive Summary
Revolution Medicines announced FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma on August 26, 2026, based on Phase 3 RASolute 302 data. The oral therapy is now available in the U.S. with a wholesale acquisition cost of $39,800 per 30-day supply. This is a transformative milestone for the company, converting its lead pipeline asset to a commercial product in a large unmet-need indication.
Key Facts
- FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent therapy is not an option.
- Approval based on Phase 3 RASolute 302 trial vs. investigator's choice chemotherapy.
- Once-daily oral tablets immediately available for prescribing in the U.S.
- Wholesale acquisition cost is $39,800 for a 30-day supply at the recommended dose.
- Company is Revolution Medicines, Inc. (ticker: RVMD), a late-stage biotech with a $45.3B market cap.
Financial Impact
First approved product, pricing at ~$39,800/month. For a pancreatic cancer indication with estimated ~60,000 new U.S. cases/year (of which ~80% are metastatic), even capturing 5-10% of the eligible second-line-plus population could represent annualized revenue in the hundreds of millions to low billions, subject to label uptake, competition, and reimbursement.
Risk Factors
- Competition from other RAS pathway inhibitors (e.g., Amgen's Lumakras, Mirati's Krazati, or future pan-RAS drugs) could limit market share.
- Reimbursement and formulary access for a high-priced oral oncolytic may be slow in the second-line+ pancreatic setting.
- Pancreatic adenocarcinoma is a difficult-to-treat cancer; real-world survival data may not fully replicate trial results.
- Stock already at $45B market cap—priced for substantial commercial success, leaving limited upside if uptake disappoints.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-366931 |
| Document: 0001193125-26-366931-index.html | 0001193125-26-366931 |
| Document: 0001193125-26-366931.txt | 0001193125-26-366931 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.29 (+0.70%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.29 (+0.70%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.29 (−2.41%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.29 (+9.01%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.29 (+10.02%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.29 (+24.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access